References
- Schmidt AF, Pearce LS, Wilkins JT, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2017;4:CD011748
- Sabatine MS, Giugliano RP, Keech AC, et al.; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713-22
- Cholesterol Treatment Trialists’ (CTT) Collaborators; Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90
- Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016;37:2999-3058
- Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004;23:1351-75. Erratum in: Stat Med 2006;25:2700
- Harbord RM, Higgins JPT. Meta-regression in Stata. In: Meta-Analysis in Stata: an updated collection from the Stata Journal, 2nd edn. Stata Press, 2016
- Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Blackwell, 2011
- Ginsberg HN, Rader DJ, Raal F, et al. ODYSSEY HIGH FI efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia. Conference abstract. 2014. Available at: https://www.my.americanheart.org/idc/groups/ahamahpublic/@wcm/@sop/@scon/documents/downloadable/ucm_469651.pdf. [Last accessed 1 October 2017]
- Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 2015;36:2996-3003
- Baigent C, Keech A, Kearney PM, et al.; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78. Errata in: Lancet 2005;366:1358; Lancet 2008;371:2084
- Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81
- Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 2016;316:1289-97
- Gulizia M, Colivicchi M, Ricciardi G, et al. Documento di consenso intersocietario ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICRIACPR/SICIGISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Colesterolo e rischio cardiovascolare: percorso diagnostico-terapeutico in Italia. G Ital Cardiol 2016;17(6Suppl1):3-57S
- Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med 2006;145:520-30
- Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012;307:1302-9. Errata in: JAMA 2012;307:1915; JAMA 2012;307:1694
- Cannon CP, Blazing MA, Giugliano RP, et al.; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97
- Simpson WG. Statins for people at low risk of cardiovascular disease. Lancet 2012;380:1815-16
- Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes 2012;5:2-5
- Takagi H, Umemoto T; ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. Limit to benefits of large reductions in low-density lipoprotein cholesterol levels: use of fractional polynomials to assess the effect of low-density lipoprotein cholesterol level reduction in metaregression of large statin randomized trials. JAMA Intern Med 2013;173:1028-9
- Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic heart disease taking statin treatment. JAMA Intern Med 2016;176:1105-13
- Ravnskov U, Diamond DM, Hama R, et al. Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review. BMJ Open 2016;6:e010401